Purified triamcinolone acetonide as antifibrotic adjunct in glaucoma filtering surgery
SourceGraefe's Archive for Clinical and Experimental Ophthalmology, 251, 4, (2013), pp. 1213-8
Article / Letter to editor
Display more detailsDisplay less details
Graefe's Archive for Clinical and Experimental Ophthalmology
SubjectNCEBP 2: Evaluation of complex medical interventions IGMD 1: Functional imaging; NCEBP 2: Evaluation of complex medical interventions IGMD 3: Genomic disorders and inherited multi-system disorders
BACKGROUND: The purpose of this study is to compare the effects of mitomycin C (MMC) and triamcinolone acetonide (TAC) during and after glaucoma filtering surgery. METHODS: Retrospective interventional consecutive case series. All eyes underwent primary guarded trabeculectomy with either MMC or sub-Tenon TAC injection. Intraoperative and postoperative complications up to 5 years after the filtering surgery were evaluated. Differences between the two regimens were tested for statistical significance. RESULTS: A total of 64 trabeculectomies, of which 39 with MMC and 25 with TAC, were compared. At the 5-year follow-up examination three of the eyes treated with MMC (7.7 %) and none of the eyes treated with TAC had an intraocular pressure of more than 18 mmHg (p = 0.08). In the MMC group, three eyes required repeated glaucoma surgery (7.7 %; one trabeculectomy, one Baerveldt drainage implant, one cyclodiode laser treatment), while this was two eyes in the TAC group (8.0 %; one Baerveldt drainage implant, one cyclodiode laser treatment) (p = 0.97). CONCLUSION: The present study demonstrates that in primary trabeculectomy, the 5-year risk profiles of MMC and purified TAC are comparable, suggesting that as an antifibrotic agent TAC is at least as effective as MMC. Prospective randomized trials will need to confirm the agents' relative long-term benefits.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.